Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of endothelial Dlc1 in embryonic vascular development and adult bone marrow hematopoiesis.

Leukemia·2026
Same author

Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines.

The Lancet. Microbe·2026
Same author

The Biomarkers Consortium: 20 years of advancing precision medicine.

Nature reviews. Drug discovery·2026
Same author

Development of HPV 35 serology assays for assessment of immune responses to HPV 35 after infection and vaccination.

Human vaccines & immunotherapeutics·2026
Same author

Noninferiority of One HPV Vaccine Dose to Two Doses.

The New England journal of medicine·2025
Same author

Knowledge and acceptability of male HPV vaccination among young people and community stakeholders in northwest Tanzania: social sciences in the Add-Vacc trial.

Vaccine·2025

Related Experiment Video

Updated: Jul 20, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

Margaret Stanley1, Douglas R Lowy, Ian Frazer

  • 1Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, UK. mas1001@cam.ac.uk

Vaccine
|September 5, 2006
PubMed
Summary

Human papillomavirus (HPV) virus-like particle (VLP) vaccines generate persistent antibodies, offering protection against HPV infection. Research is ongoing to establish immune correlates of protection and address duration and genotype replacement.

Related Experiment Videos

Last Updated: Jul 20, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Human papillomavirus virus-like particles (VLPs) are synthesized from the L1 capsid protein.
  • HPV L1 VLPs mimic native virions, forming the basis for subunit vaccines.
  • These vaccines induce high, persistent antibody titers against L1 VLPs.

Purpose of the Study:

  • To review the current understanding of HPV L1 VLP vaccines.
  • To discuss the assumed mechanism of protection via serum neutralizing Immunoglobulin G (IgG).
  • To identify key areas for future research, including immune correlates, duration of protection, and genotype replacement.

Main Methods:

  • Review of existing literature on HPV L1 VLP vaccines.
  • Analysis of antibody responses and vaccine efficacy data.
  • Discussion of immunological principles related to vaccine-induced protection.

Main Results:

  • HPV L1 VLP vaccines elicit high antibody titers that persist for at least 48 months.
  • Protection is presumed to be mediated by serum neutralizing IgG antibodies.
  • Neutralizing antibodies are predominantly type-specific, with limited cross-neutralization among homologous HPV types.

Conclusions:

  • HPV L1 VLP vaccines are effective in inducing persistent antibody responses.
  • Immune correlates of protection remain to be definitively established due to limited vaccine failures.
  • Further investigation is needed on the duration of protection and the phenomenon of genotype replacement.